OREANDA-NEWS  The Federal Antimonopoly Service (FAS) of Russia has agreed on prices for the second domestic anticancer generic drug Regorafenib-Amedart under the international nonproprietary name of the same name, the agreed price is 50% lower than the registered price for the foreign-made reference drug Stivarga, the agency said.

"Prices for the anticancer drug Regorafenib-Amedart have been reduced by 50%. This is the second generic under the international nonproprietary name of the same name," the report says.

The agreed marginal selling prices for the drug have been reduced by 50% relative to the registered price of a foreign-made reference drug, Stivarga, the service adds.